Protagenic Therapeutics, Inc. received a notification from Nasdaq on November 19, 2024, regarding non-compliance with the minimum stockholders’ equity requirement of $2,500,000, and has appealed the decision with a hearing scheduled for January 30, 2025. Nasdaq has stayed the delisting action pending the Panel's final decision, as of the filing date on December 3, 2024.

Protagenic Therapeutics, Inc. received a notification from Nasdaq on January 29, 2025, indicating it failed to meet the minimum bid price requirement of $1.00 per share and was given until January 21, 2025, to regain compliance, which it did not achieve. The company is scheduled to present its case to the Nasdaq Hearings Panel on January 30, 2025, to address its listing status. On February 19, 2025, the Company received a hearing panel decision from Nasdaq (Nasdaq Listing Qualifications Hearings Docket No. NQ 7072C-25) indicating that its provisional plan for regaining compliance with the Nasdaq listing requirements had been accepted. For continued listing on the Nasdaq Capital Market, the Company has until April 28, 2025 to: (1) demonstrate compliance with Nasdaq Rules 5550(a)(2) and 5550(b)(2), (2) file a public disclosure describing any transactions undertaken by the Company to increase its equity and provide and indication of its equity following those transactions, and (3) provide the Panel with an update on its fundraising plans and updated income projections for the next 12 months. Filed At: 2025-03-31.

Protagenic Therapeutics, Inc. received a notification from Nasdaq for not holding its annual meeting of shareholders within the required timeframe following the end of its fiscal year on December 31, 2023. The company has scheduled its annual meeting to occur no later than February 21, 2025, and is working to address this compliance issue, with the notification not currently affecting the listing of the company's securities on the Nasdaq Capital Market. Filed At: 2025-01-15.